IP Library Granted Patent US 8,084,252
Granted Patent B2
US 8,084,252 · App. 12/848,897 · Granted Dec 27, 2011

Recombinant cell clones having increased stability and methods of making and using the same

Assignee: Baxter Innovations GmbH
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,084,252
App. No.
12/848,897
Granted
Dec 27, 2011
Kind
B2
Abstract

Disclosed are a stable recombinant cell clones which are stable in serum- and protein-free medium for at least 40 generations, a biomass obtained by multiplying the stable cell clone under serum- and protein-free culturing conditions, and a method of preparing recombinant proteins by means of the biomass. Furthermore, the invention relates to a method of recovering stable recombinant cell clones.

Claims (28)

1. A method for preparing a recombinant polypeptide in a cell culture, comprising: multiplying an isolated stable mammalian recombinant cell clone that has a selection marker and contains a sequence encoding the recombinant polypeptide in a serum- and protein-free medium comprising a mixture of amino acids containing L-asparagine, L-cysteine, L-cystine, L-proline, L-tryptophan and L-glutamine, wherein the stable cell clone is cultured with neither selective pressure for the selection marker nor selection for a polypeptide factor that replaces serum components, preparing a cell culture containing the stable cell clone in a bioreactor, and harvesting the recombinant polypeptide from the culture supernatant.

2. A method of claim 1 , wherein L-asparagine, L-cysteine, L-cystine, or L-tryptophan in the mixture is present from about 1 mg/l to about 100 mg/l.

3. A method of claim 1 , wherein L-proline in the mixture is present from about 1 mg/l to about 150 mg/l.

4. A method of claim 1 , wherein L-glutamine in the mixture is present from about 50 mg/l to about 1000 mg/l.

5. A method of producing a recombinant product under serum- and protein-free conditions on a large technical scale comprising the steps of:

providing an isolated, stable recombinant original cell clone that contains a selection marker, said original cell clone being stable in serum- and protein-free medium for at least 40 generations and expressing a recombinant product,

multiplying said original stable cell clone in serum- and protein-free medium with neither selective pressure for the selection marker nor selection for a polypeptide factor that replaces serum components so as to obtain a cell culture,

culturing said cell culture containing stable cells in a bioreactor, thereby obtaining said recombinant product, and

harvesting said recombinant product from a supernatant of said cell culture.

6. A method of claim 5 , wherein said original cell clone is stable in serum- and protein-free medium for at least 50 generations.

7. A method of claim 5 , wherein said serum- and protein-free medium is a synthetic minimum medium and further comprises ultrafiltrated soybean peptone.

8. A method of producing a recombinant polypeptide in a cell culture comprising the steps of:

multiplying an isolated stable starting cell clone containing a selection marker expressing a recombinant polypeptide in serum- and protein-free medium with neither selective pressure for the selection marker nor selection for a polypeptide factor that replaces serum components so as to obtain a cell culture,

culturing said cell culture containing stable cells in a bioreactor so as to obtain a cell culture, and

harvesting said recombinant polypeptide from a supernatant of said cell culture.

9. A method of claim 8 , wherein the serum- and protein-free medium comprises minimum medium and ultrafiltrated soybean peptone.

10. The method of claim 1 , wherein the recombinant polypeptide is Factor VIII.

11. The method of claim 1 , wherein the recombinant polypeptide is Factor IX.

12. The method of claim 1 , wherein the recombinant polypeptide is Factor VII.

13. The method of claim 1 , wherein the recombinant polypeptide is von Willebrand factor (vWF).

14. The method of claim 5 , wherein the recombinant product is Factor VIII.

15. The method of claim 5 , wherein the recombinant product is Factor IX.

16. The method of claim 5 , wherein the recombinant product is Factor VII.

17. The method of claim 5 , wherein the recombinant product is vWF.

18. The method of claim 8 , wherein the recombinant polypeptide is Factor VIII.

19. The method of claim 8 , wherein the recombinant polypeptide is Factor IX.

20. The method of claim 8 , wherein the recombinant polypeptide is Factor VII.

21. The method of claim 8 , wherein the recombinant polypeptide is von Willebrand factor (vWF).

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 19, 2015
From: BAXTER INTERNATIONAL INC.; BAXTER HEALTHCARE SA
To: BAXALTA INCORPORATED; BAXALTA GMBH
Reel/Frame 036825/0963 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 16, 2015
From: BAXTER INNOVATIONS GMBH
To: BAXTER INTERNATIONAL INC.; BAXTER HEALTHCARE S.A.
Reel/Frame 035424/0172 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 14, 2011
From: REITER, MANFRED; MUNDT, WOLFGANG; DORNER, FRIEDRICH
To: BAXTER AKTIENGESELLSCHAFT
Reel/Frame 026902/0994 →
CHANGE OF NAME Recorded Mar 7, 2011
From: BAXTER AKTIENGESELLSCHAFT
To: BAXTER INNOVATIONS GMBH
Reel/Frame 025914/0023 →
Priority Claims (1)
AT 1073/97 · Jun 20, 1997 · national
Continuity (7)
Division 12488465 · Jun 19, 2009
Continuation 11482504 · Jul 7, 2006
Division 11123362 · May 6, 2005
Continuation 10170661 · Jun 12, 2002
Continuation 09324612 · Jun 2, 1999
Continuation In Part 09100253 · Jun 19, 1998
Related Publication 20100317055A1 · Dec 16, 2010